Ratings
0
Nobody has rated this yet. Be the first!
Works
4
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
